Assessment of the Anticoagulant Effect of Curcumin as Adjuvant Therapy to Enoxaparinin Covid-19 Iraqi Patients

Abstract

Objective: To assess the anticoagulant effect of curcumin as adjuvant treatment to enoxaparin in COVID-19 patients. 
Study Design: Randomized open-labelled controlled trial study. 
Place and Duration of Study: This study was conducted at the College of Pharmacy, Al-Esraa University, Baghdad, Iraq from 1st February 2020 to 31st July 2020. 
Methods: Fifty-eight patients with confirmed Covid19 were enrolled into 2 groups: Group A; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs. Group B; 29 patients were given Enoxaparin prophylactic dose 4000 IU twice daily every 12 hrs + Curcumin 500 mg 3 times daily. 
Results: A significantly higher level of improvement in the outcomes of D-dimer serum level in the group treated  with enoxaparin and curcumin in comparison with group A which was treated with enoxaparin alone (P<0.05). 
Conclusion: The overall results of this clinical study showed a significant D-dimer reduction by curcumin supplementation as well as reducing mortality and enhancing the overall clinical outcome of the treatment when used as an adjunct to enoxaparin.